Feed/Investors/Advent Life Sciences

Advent Life Sciences

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

Since 2025-04-16

ROUNDS

as lead investor

LED ROUNDS · USD

$38.3M

across 1 round · 1 co-led, split evenly

LATEST ROUND

Series C · $115M · 2025-04-16

CO-INVESTORS

named beside it

Rounds

[ 1 ]

The rounds this investor is named on, who it invests beside, and where it shows up.

Company	Round	Amount	Announced	Role
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments.	Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$115M	2025-04-16	[ LEAD ]